Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation

[1] Schnabel RB(2015)50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study Lancet 386 154-162

[2] Yin X(2006)Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 119-125

[3] Gona P(2015)Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs Lancet 386 303-310

[4] Larson MG(2014)Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial JAMA 312 1988-1998

[5] Beiser AS(2015)Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation J Am Coll Cardiol 65 2614-2623

[6] McManus DD(2016)Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug EuroIntervention 11 1170-1179

[7] Newton-Cheh C(2013)Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy J Am Coll Cardiol 62 96-102

[8] Lubitz SA(2013)Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation J Am Coll Cardiol 61 2551-2556

[9] Magnani JW(2017)5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials J Am Coll Cardiol 70 2964-2975

[10] Ellinor PT(2009)Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study JACC Cardiovasc Interv 2 594-600

[1] Schnabel RB(2015)50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study Lancet 386 154-162

[2] Yin X(2006)Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 119-125

[3] Gona P(2015)Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs Lancet 386 303-310

[4] Larson MG(2014)Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial JAMA 312 1988-1998

[5] Beiser AS(2015)Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation J Am Coll Cardiol 65 2614-2623

[6] McManus DD(2016)Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug EuroIntervention 11 1170-1179

[7] Newton-Cheh C(2013)Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy J Am Coll Cardiol 62 96-102

[8] Lubitz SA(2013)Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation J Am Coll Cardiol 61 2551-2556

[9] Magnani JW(2017)5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials J Am Coll Cardiol 70 2964-2975

[10] Ellinor PT(2009)Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study JACC Cardiovasc Interv 2 594-600